OxyCOP is a clinical multicenter cluster randomized trial investigating controlled oxygen therapy in patients admitted with acute exacerbation of chronic obstructive pulmonary disease. We aim to determine whether using a strategy with a moderate oxygen target (SpO2 93-96%), compared to a low oxygen target SpO2 88-92%, leads to shorter admission and lower mortality. Expected start is February 2024
THERM-A-LUNG is the first investigator-initiated, randomized, controlled trial to examine whether systematic, frequent sauna bathing can reduce/eradicate pathogenic, colonizing bacteria in the lungs, induce changes in the lung microbiota and improve prognosis in people with persistent, antibiotic-resistant lung infections compared to no sauna bathing.
Study protocol (download)
We are currently running a trial with the aim to determine if a time-updated, eosinophil-guided inhaled corticosteroid treatment in patients with severe and very severe COPD can lead to non-inferior treatment responses to standard treatment with combined ICS, LAMA and LABA, and whether the side-effects of ICS can be reduces by this guided administration. Furthermore, whether the use of azithromycin can reduce the time hospitalized with AECOPD (or other cause) in severe COPD patients
We have completed a trial with the hypothesis that in patients who are urgently admitted and who have a positive test for 2019-nCoV and symptoms similar to COVID-19 disease, treatment with corona virus inhibitor hydroxychloroquine as well as virus-immunomodulatory and antibacterial drug azithromycin can lead to shorter hospitalisation and fewer admissions in the intensive care unit. Results were neutral in all outcomes.
Read more about the trial and look through our publications.
Anvendelsen af inhalerede kortikosteroider hos ambulante patienter med KOL er forbundet med en dosisafhængig stigning i risikoen for at isolere H. Influenzae. Denne observation understøtter, at højdosis inhalerede kortikosteroider bør
Reaktioner på COVID-19 vaccinationen hos patienter med kroniske lungesygdomme er ringe karakteriseret. I dette studie havde vi til formål at beskrive humorale responser efter to doser af BNT162b2 mRNA COVID-19
